While the prevalence of Lyme disease and other illnesses spread by ticks has steadily increased in the United States over the past 20 years, a new study of the state of American tick surveillance and control reveals an inconsistent and often under-supported patchwork of programs across the country. For instance, while about two-thirds of tick management programs engage in passive tick surveillance, such as accepting tick samples submitted by the public, only 46 percent engage in routine active tick surveillance, such as focused collection of tick samples in the field.

Northeast Regional Center for Excellence in Vector-Borne Diseases

ANNAPOLIS, MD June 17, 2020 While the prevalence of Lyme disease and other illnesses spread by ticks has steadily increased in the United States over the past 20 years, a new study of the state of American tick surveillance and control reveals an inconsistent and often under-supported patchwork of programs across the country.

Annually reported cases of tickborne disease more than doubled between 2004 and 2018, according to the US Centers for Disease Control and Prevention (CDC), while seven new tickborne germs were discovered in that same timeframe. But a clear gap exists in our public health infrastructure, say researchers who have conducted the first-ever survey of the nation's tick management programs.

The survey showed that less than half of public health and vector-control agencies engage in active tick surveillance, and only 12 percent directly conduct or otherwise support tick-control efforts. These and other findings from the survey, conducted by university researchers at the CDC's five Vector-Borne Disease Regional Centers of Excellence, were published June 17 in theJournal of Medical Entomology.

"Ticks are responsible for the majority of our vector-borne illnesses in the US, and our programming does not adequately meet the need in its current form, for both surveillance and control," says Emily M. Mader, MPH MPP, lead author on the study and program manager at the Northeast Regional Center for Excellence in Vector-Borne Diseases, housed at Cornell University.

Mader and colleagues surveyed 140 vector-borne disease professionals working at state, county, and local agencies in the fall of 2018 to learn about their program objectives and capabilities for tick surveillance and control, testing ticks for disease-causing germs, and barriers to success. Reaching even that many respondents proved challenging, as no central database of tick-management programs or contacts was available.

The blacklegged tick (Ixodes scapularis), shown here in multiple life stages suspended in a vial.

Northeast Regional Center for Excellence in Vector-Borne Diseases

Highlights from the survey of tick-management programs include:

Less than half of tick-management programs proactively collect ticks in their area. While about two-thirds of respondents (65 percent) said their programs engage in passive tick surveillance, such as accepting tick samples submitted by the public, only 46 percent said their programs engage in routine active tick surveillance, such as focused collection of tick samples within their community.

Only a quarter of tick-management programs test ticks for disease-causing germs. Just 26 percent of survey respondents said their jurisdiction conducts or financially supports testing of tick samples for disease-causing pathogens. And only seven percent said their programs work to evaluate the presence of such pathogens in the animal hosts (such as mice and other rodents) from which ticks acquire those pathogens in their area.

"Pathogen testing is an essential component of surveillance and is needed in order to understand tickborne disease risk to communities," says Mader. "There appears to be a significant barrier for many tick-surveillance programs across the country to access pathogen-testing services."

Capacity for public tick-control efforts is low. Only 12 percent of respondents said that their jurisdiction conducts or financially supports tick control, with those efforts primarily focused reducing tick presence on animal hosts (such as deer and rodents).

Mader says limited resources mean tick-management programs need reliable, proven control methods. "They are not going to invest in a strategy unless it has been investigated and shown to make a difference in reducing the burden of ticks and tickborne diseases," she says. "Right now, supporting this research is a major need. These kinds of evaluations often take at least three years to complete and require a significant investment."

Tick surveillance and control happen in a range of sectors. The most common employment sectors among respondents being public health, mosquito control, cooperative extension, and agriculture. And more than half of respondents (57 percent) said their programs work with academic partners to conduct tick surveillance.

"The world of ticks reaches entomologists, veterinarians, medical doctors, public health, natural resource managers, farmers, pet owners, scientists, and anyone that enjoys the outdoors," says Nohra Mateus-Pinilla, PhD, co-author on the study and director of the Veterinary Epidemiology Laboratory at the University of Illinois's Illinois Natural History Survey. "The partnerships stand out because broad, collaborative networks are paramount to a positive and productive path for the advancement of this field."

Info and data sharing on ticks and public health is lagging. Less than a quarter of respondents said their tick-management programs disseminate information to local health departments (23 percent) or report data to the CDC (14 percent).

Greater support for tick-management programs is critical. To improve tick-management programs, respondents commonly cited the need for stable funding, training for personnel, and standardized, research-based guidance and protocols.

Tick surveillance and control happen across a range of sectors, the most common being public health, mosquito control, cooperative extension, and agriculture. More than half of tick management programs also work with academic partners to conduct tick surveillance.

Northeast Regional Center for Excellence in Vector-Borne Diseases

In December 2019, the Kay Hagan Tick Act was signed into federal law, authorizing $150 million to strengthen various aspects of the nation's efforts to vector-borne disease, including reauthorization of the CDC's Vector-Borne Disease Regional Centers of Excellence for an additional five years, through 2026. The CDC also issued guidance documents in late 2018 and early 2020 to provide tick-management programs with best practices for surveillance of blacklegged tick species (Ixodes scapularis and Ixodes pacificus) and other hard tick species across the US.

These steps address needs revealed in the survey of tick-management programs, and Mader and Mateus-Pinilla say the survey will serve as an important baseline from which to measure future progress and improvement.

"Overall, tick-work demands a long-term commitment. Ticks can take years to complete their life cycle, use different hosts to move around, and take advantage of weather and habitat changes," says Mateus-Pinilla. "As such, research on these vectors requires long-term and sustained commitment to research, surveillance, and partnerships across a broad range of disciplines, health professionals, and the public."

- This press release was originally published onEntomology Today, the Entomological Society of America's news website

Read more from the original source:
Study: Tick Surveillance and Control Lagging in US - Lab Manager Magazine

Cat Litter Box Industry 2020 Global Market Research report presents a widespread and elementary study of Cat Litter Box business at the side of the analysis market size, share, trends growth, revenue, production and 2025 forecast. This report also gives you the analytical data of market, like consumption volume, and Cat Litter Box Market price structures throughout the forecast amount from 2020 to 2025.

The report forecast global Cat Litter Box market to grow to reach xxx Million USD in 2020 with a CAGR of xx% during the period 2020-2026.The report offers detailed coverage of Cat Litter Box industry and main market trends. The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading Cat Litter Box by geography. The report splits the market size, by volume and value, on the basis of application type and geography.

You Can Get a Sample Copy of this Report at https://www.orianresearch.com/request-sample/1471754

Major Players in Cat Litter Box market are:

The scope of the Global Cat Litter Box Report:

Order a copy of Global Cat Litter Box Market Report @ https://www.orianresearch.com/checkout/1471754

Market by Type

Electric TypeNormal Type

Market by Application

OnlineOffline

Important Aspects of Cat Litter Box Report:

Why To Select This Report:

Complete analysis on market dynamics, market status and competitive Cat Litter Box view is offered.

Forecast Global Cat Litter Box Industry trends will present the market drivers, constraints and growth opportunities.

The five-year forecast view shows how the market is expected to grow in coming years.

All vital Global Cat Litter Box Industry verticals are presented in this study like Product Type, Applications and Geographical Regions.

Table of Contents

Part 1 Market Overview

Part 2 Global Market Status and Future Forecast

Part 3 Asia-Pacific Market Status and Future Forecast

Part 4 Asia-Pacific Market by Geography

Part 5 Europe Market Status and Future Forecast

Part 6 Europe Market by Geography

Part 7 North America Market Status and Future Forecast

Part 8 North America Market by Geography

Part 9 South America Market Status and Future Forecast

Part 10 South America Market by Geography

Part 11 Middle East & Africa Market Status and Future Forecast

Part 12 Middle East & Africa Market by Geography

Part 13 Key Companies

Part 14 Conclusion

Customization Service of the Report:-

Orian Research provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities

About Us:Orian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Contact Us:

Ruwin Mendez

Vice President Global Sales & Partner Relations

Orian Research Consultants

US +1 (415) 830-3727| UK +44 020 8144-71-27

Email: [emailprotected]

View post:
Cat Litter Box Market 2020 Size, Share, Sales Revenue, Business Trends, Emerging Opportunities, Demand, Key Companies Strategies, New Applications and...

Persistence Market Research (PMR) has published a new research report on canine stem cell therapy. The report has been titled, Canine Stem Cell Therapy Market: Global Industry Analysis 2016 and Forecast 20172026.Veterinary research has been used in regenerative and adult stem cell therapy andhas gained significant traction over the last decade.

Canine stem cell therapy products are identified to have gained prominence over the past five years, and according to the aforementioned research report, the market for canine stem cell therapy will expand at a moderate pace over the next few years.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/15550

Company Profiles

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/15550

Though all animal stem cells are not approved by FDA, veterinary stem-cell manufacturers and university researchers have been adopting various strategies in order to meet regulatory approvals, and streamline and expedite the review-and-approval process. The vendors in the market are incessantly concentrating on research and development to come up with advanced therapy, in addition to acquiring patents.

In September 2017, VetStem Biopharma, Inc. received European patent granted to the University of Pittsburgh and VetStem received full license of the patent then. This patent will eventually provide the coverage for the ongoing commercial and product development programs of VetStem and might be also available for licensing to other companies who are rather interested in this field.

The other companies operating in the global market for canine stem cell therapy are VETherapy Corporation, Aratana Therapeutics, Inc., Regeneus Ltd, Magellan Stem Cells, Animal Cell Therapies, Inc., and Medrego, among others.

According to the Persistence Market Research report, the globalcanine stem cell therapy marketis expected to witness a CAGR of 4.2% during the forecast period 2017-2026. In 2017, the market was valued at US$ 151.4 Mn and is expected to rise to a valuation of US$ 218.2 Mn by the end of 2026.

Burgeoning Prevalence of Chronic Diseases in Dogs to Benefit Market

Adipose Stem Cells (ASCs) are the most prevalent and in-demand adult stem cells owing to their safety profile, ease of harvest, and use and the ability to distinguish into multiple cell lineages. Most early clinical research is focused on adipose stem cells to treat various chronic diseases such as arthritis, tendonitis, lameness, and atopic dermatitis in dogs.

A large area of focus in veterinary medicine is treatment of osteoarthritis in dogs, which becomes more prevalent with age. Globally, more than 20% dogs are suffering from arthritis, which is a common form of canine joint and musculoskeletal disease. Out of those 20%, merely 5% seem to receive the treatment.

However, elbow dysplasia in canine registered a prevalence rate of 64%, converting it into an alarming disease condition to be treated on priority. Thereby, with the growing chronic disorders in canine, the demand for stem cell therapy is increasing at a significant pace.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/15550

Expensive Nature of Therapy to Obstruct Growth Trajectory

Expensive nature and limited access to canine stem cell therapy has demonstrated to be a chief hindrance forestalling its widespread adoption. The average tier II and tier III veterinary hospitals lack the facilities and expertise to perform stem cell procedures, which necessitates the referral to a specialty vet hospital with expertise veterinarians.

A trained veterinary physician charges high treatment cost associated with stem cell therapy for dogs. Generally, dog owners have pet insurance that typically covers maximum cost associated with steam cell therapy to treat the initial injury but for the succeeding measures in case of retreatment, the costs are not covered under the pet insurance. The stem cell therapy is thus cost-prohibitive for a large number of pet owners, which highlights a major restraint to the market growth. Stem cell therapy is still in its developmental stage and a positive growth outcome for the market cannot be confirmed yet.

Here is the original post:
How Corona Pandemic will Impact Canine Stem Cell Therapy Market Business Opportunity, and Growth 2026 - Cole of Duty

The majority of patients with early stage unfavorable Hodgkin lymphoma respond well enough to a current standard regimen of 4 cycles of chemotherapy, and can skip the additional radiotherapy that is normally included in the combined modality treatment, say experts reporting the final results from an international phase 3 randomized trial dubbed HD17.

"Most patients with this disease will not need radiotherapy any longer," concluded first author Peter Borchmann, MD, assistant medical director in the Department of Hematology/Oncology at the University Hospital of Cologne, Germany.

Borchmann was speaking online as part of the virtual edition of the European Hematology Association (EHA) 25th Annual Congress 2020.

"Importantly, the mortality of patients with early stage unfavorable Hodgkin lymphoma in the HD17 study did not differ from the normal healthy German population, and this is the first time we have had this finding in one of our studies," he emphasized.

Borchmann added that positron emission tomography (PET) imaging is key in deciding which patients can skip radiation.

"We conclude from the HD17 trial that the combined modality concept can and should be replaced by a PET-guided omission of radiotherapy for patients with newly diagnosed early stage unfavorable Hodgkin lymphoma," he said.

"The vast majority of early stage unfavorable Hodgkin lymphoma patients can be treated with the brief and highly effective 2+2 chemotherapy alone," he added.

Therefore, he continued, "PET-guided 2+2 chemotherapy is the new standard of care for the German Hodgkin study group," which conducted the trial.

The use of both chemotherapy and radiation has long been a standard approach to treatment, and this combined modality treatment is highly effective, Borchmann explained. But it can cause long-term damage, and the known longer-term negative effects of radiotherapy, such as cardiovascular disease and second malignancies, are a particular concern because patients with early stage Hodgkin lymphoma are relatively young, with a median age of around 30 years at disease onset.

An expert approached for comment said that the momentum to skip radiotherapy when possible is an ongoing issue, and importantly, this study adds to those efforts.

"The treatment of Hodgkin lymphoma has moved for many years now to less radiation therapy, and this trend will continue with the results of this study," commented John G. Gribben, MD, director of the Stem Cell Transplantation Program and medical director of the North East London Cancer Research Network Centre at Barts Cancer Center of Excellence and The London School of Medicine, UK.

"We have moved to lower doses and involved fields with the intent of decreasing toxicity, and particularly long-termtoxicity from radiotherapy," he told Medscape Medical News.

For the multicenter, phase 3 HD17 trial, Borchmann and colleagues turned to PET to identify patients who had and had not responded well to chemotherapy (PET-negative and PET-positive) and to determine if those who had responded well could safely avoid radiotherapy without compromising efficacy.

We wanted to determine if we could reduce the treatment intensity by omission of radiotherapy in patients who respond very well to the systemic treatment, so who have a complete metabolic remission after the chemotherapy, Borchmann said.

The 2+2 treatment approach includes 2 cycles of eBEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) and 2 subsequent cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine).

The trial enrolled 1100 patients with newly diagnosed Hodgkin lymphoma between January 2012 and March 2017. Of these, 979 patients had confirmed PET results, with 651 (66.5%) found to be PET-negative, defined as having a Deauville score (DS) of less than 3 (DS3); 238 (24.3%) were DS3 and 90 (9.2%) were DS4.

The study met its primary endpoint of noninferiority in progression-free survival (PFS) at 5 years, with a PFS of 95.1% in the PET-guided group (n = 447) compared with 97.3% in the standard combined-modality treatment group (n = 428), over a median observation time of 45 months, for a difference of 2.2% (P = .12).

"We found that the survival levels were very high and we can safely conclude the noninferiority of the PET-guided approach in PET-negative patients," Borchmann said.

A further analysis showed that the 597 PET-negative patients who did not receive radiotherapy due to their PET status had 5-year PFS that was noninferior to the combined modality group (95.9% vs 97.7%, respectively; P = .20).

And among 646 patients who received the 2+2 regimen plus radiotherapy, of thoseconfirmed as PET-positive (n = 328), the estimated 5-year PFS was significantly lower (94.2%) compared with those determined to be PET-negative (n = 318; 97.6%; hazard ratio, 3.03).

A cut-off of DS4 for positivity was associated with a stronger effect, with a lower estimated 5-year PFS of 81.6% vs 98.8% for DS3 patients and 97.6% for DS < 3 (P < .0001).

"Only DS4 has a prognostic impact, but not DS3," Borchmann said. "DS4 positivity indicates a relevant risk for treatment failure, however, there are few patients in this risk group (9.2% in this trial)."

The 5-year overall survival rates in an intent-to-treat analysis were 98.8% in the standard combined modality group and 98.4% in the PET-guided group.

With a median observation time of 47 months, there have been 10 fatal events in the trial out of 1100 patients, including two Hodgkin lymphoma-related events and one treatment-related death.

"Overall, Hodgkin lymphoma or treatment-related mortality rates were extremely low," Borchmann said.

The study was funded by Deutsche Krebshilfe. Borchmann and Gribben have reported no relevant financial relationships.

EHA 2020 Congress. Presented June 12, 2020. Abstract S101.

For more from Medscape Oncology, join us on Twitter and Facebook.

Read more here:
Safe to Skip Radiotherapy With Negative PET in Hodgkin Lymphoma - Medscape

Stimulating stem cells to heal faster through the use of shock wave therapy is part of the exciting new research by a Canadian veterinarian.

Dr Judith Koenig, a clinician, researcher and instructor at the Ontario Veterinary College (OVC), is investigating whether shock wave therapy performed after injecting stem cells into a tendon will result in better quality healing. Her research team then came up with the idea of pre-treating stem cells with shock wave prior to injection.

Koenig is also leading a clinical trial, currently enrolling thoroughbred racehorses. The trial performs repeated injection of stem cells that have been harvested from umbilical cord blood, frozen and stored in Dr Thomas Kochs lab. These stem cells are from unrelated horses. Funding from the Ontario Equestrian federation has enabled OVC researchers to also follow a control group treated with platelet-rich plasma as a comparison for this study.

Reduced healing time is an obvious benefit to the welfare of the horse and the horse owner will be pleased about a quicker return to their training rgime.

Lameness is a huge focus for Koenig, who is also a rider with a keen interest in helping grassroots riders and upcoming high-performance athletes.

Realizing many will soon be in the position of starting horses back into training after a significant amount of time off, Koenig offers some important advice.

You need to allow at least a six-week training period for the athletes to be slowly brought back and build up muscle mass and cardiovascular fitness, she says. Both stamina and muscle mass need to be retrained.

She stressed the importance in checking the horses legs for heat and swelling before and after every ride and picking out the feet.A good period of walking is required in the warm-up and cool down and riders need to pay attention to soundness in the walk before commencing their work out.

Koenigs main area of interest in research is tissue healing, particularly wound and tendon healing. She has investigated the use of different modalities (for example shockwave or stem cells) to see if they accelerate tissue healing and which cellular pathways are affected. This will help to direct treatment of tendon injuries and wounds in horses.

Koenig is originally from Austria and moved to Canada 1996 after graduating from vet school to gain research experience and complete the research for her MSc. Following a large animal internship at the Ontario Veterinary College she went to Oregon State University where she did a one-year large animal fellowship. The year in Oregon gave her good exposure to Western Pleasure horses as well as Walking horses, which complemented her previous experience with Sports and Racehorse practice.

She came back to the Ontario Veterinary College where she did a three-year large animal surgery residence with a concurrent graduate degree (DVSc). Koenig became board certified with both the American and European College of Veterinary Surgeons and started to work as faculty in Large Animal Surgery in 2003. Since then she has been working half of the time as a surgeon with a strong interest in Equine Sports Medicine and the other half as researcher and teacher. In 2016, Koenig became a board-certified diplomate for equine sports medicine and rehabilitation.

Excerpt from:
Shock wave therapy on stem cells focus of lameness research - Horsetalk

MGD013 is a first-in-class bispecific tetravalent DART molecule designed to bind PD-1 and LAG-3 and restore function of exhausted T cells. Results from a phase 1 study of MGD013 have shown an acceptable safety profile and early activity in patients with advanced solid tumors and hematologic malignancies.

Results of the study were presented by Jason J. Luke, MD, of University of Pittsburgh Hillman Cancer Center in Pennsylvania, during the ASCO20 Virtual Scientific Program.

The study enrolled 50 patients into a dose escalation study from 1 mg to 1200 mg every 2 weeks, and 157 patients into a cohort expansion study at the phase 2 dose of 600 mg.

About 70% of patients experienced a treatment-related adverse event, with 23.2% experiencing grade 3 or worse events. The most commonly reported adverse events were fatigue (19%) and nausea (11%).

Among the patients in the dose escalation cohort who were evaluable for response there were 3 confirmed partial responses. One occurred in a patient with triple-negative breast cancer, 1 in a patient with mesothelioma, and 1 in a patient with gastric cancer. Eighteen patients had stable disease. This resulted in a disease control rate of 48.8%.

Dr Luke note that several cohorts in the study are ongoing, including a lymphoma cohort. He highlighted 1 patient from that cohort, a 27-year-old man with diffuse large B-cell lymphoma who had progression of disease after CAR-T cell therapy. This patient was given a single dose of MGD013 at 600 mg.

A pretreatment biopsy from the patients lymph node showed high expression of PD-1 and LAG-3. After CAR-T, the patient had CD19 loss. After his dose of MGD013, the patient was admitted to the hospital on day 11 due to grade 2 cytokine release syndrome, but had a complete response on PET scan at day 24. The patient later had allogeneic stem cell transplant and is now in remission 11 months post-MGD103.

Evaluation of MGD103 as monotherapy and in combination with FC-engineered monoclonal antibodies such as margetuximab is going, Dr Luke concluded.

Read more of Cancer Therapy Advisors coverage of the ASCO 2020 meeting by visiting the conference page.

Reference

Luke JJ, Patel MR, Hamilton EP, et al. A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecular binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms. Presented at: ASCO20 Virtual Scientific Program.J Clin Oncol. 2020;38(suppl):abstr 8001.

Continued here:
Bispecific DART Molecule Targeting PD-1, LAG3 Active, Well-Tolerated - Cancer Therapy Advisor

The Canine Stem Cell Therapy Market research report enhanced worldwide Coronavirus COVID19 impact analysis on the market size (Value, Production and Consumption), splits the breakdown (Data Status 2014-2020 and 6 Year Forecast From 2020 to 2026), by region, manufacturers, type and End User/application. This Canine Stem Cell Therapy market report covers the worldwide top manufacturers like (VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana Therapeutics, Medivet Biologics, Okyanos, Vetbiologics, VetMatrix, Magellan Stem Cells, ANIMAL CELL THERAPIES, Stemcellvet) which including information such as: Capacity, Production, Price, Sales, Revenue, Shipment, Gross, Gross Profit, Import, Export, Interview Record, Business Distribution etc., these data help the consumer know about the Canine Stem Cell Therapy market competitors better. It covers Regional Segment Analysis, Type, Application, Major Manufactures, Canine Stem Cell Therapy Industry Chain Analysis, Competitive Insights and Macroeconomic Analysis.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures)of Canine Stem Cell Therapy[emailprotected]https://www.researchmoz.us/enquiry.php?type=S&repid=2081893

Canine Stem Cell Therapy Market report offers comprehensive assessment of 1) Executive Summary, 2) Market Overview, 3) Key Market Trends, 4) Key Success Factors, 5) Canine Stem Cell Therapy Market Demand/Consumption (Value or Size in US$ Mn) Analysis, 6) Canine Stem Cell Therapy Market Background, 7) Canine Stem Cell Therapy industry Analysis & Forecast 20202026 by Type, Application and Region, 8) Canine Stem Cell Therapy Market Structure Analysis, 9) Competition Landscape, 10) Company Share and Company Profiles, 11) Assumptions and Acronyms and, 12) Research Methodology etc.

Scope of Canine Stem Cell Therapy Market:The non-invasive stem cell obtaining procedure, augmented possibility of accomplishing high quality cells, and lower price of therapy coupled with high success rate of positive outcomes have collectively made allogeneic stem cell therapy a preference for veterinary physicians. Moreover, allogeneic stem cell therapy is 100% safe, which further supports its demand on a global level. Pet owners are identified to prefer allogeneic stem cell therapy over autologous therapy, attributed to its relatively lower costs and comparative ease of the entire procedure.

A rapidly multiplying geriatric population; increasing prevalence of chronic ailments such as cancer and cardiac disease; growing awareness among patients; and heavy investments in clinical innovation are just some of the factors that are impacting the performance of the global healthcare industry.

On the basis on the end users/applications,this report focuses on the status and outlook for major applications/end users, shipments, revenue (Million USD), price, and market share and growth rate foreach application.

Veterinary Hospitals Veterinary Clinics Veterinary Research Institutes

On the basis of product type, this report displays the shipments, revenue (Million USD), price, and market share and growth rate of each type.

Allogeneic Stem Cells Autologous Stem cells

Do You Have Any Query Or Specific Requirement? Ask to Our Industry[emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid=2081893

Geographically, the report includes the research on production, consumption, revenue, Canine Stem Cell Therapy market share and growth rate, and forecast (2020-2026) of the following regions:

Important Canine Stem Cell Therapy Market Data Available In This Report:

Strategic Recommendations, Forecast Growth Areasof the Canine Stem Cell Therapy Market.

Challengesfor the New Entrants,TrendsMarketDrivers.

Emerging Opportunities,Competitive Landscape,Revenue Shareof Main Manufacturers.

This Report Discusses the Canine Stem Cell Therapy MarketSummary; MarketScopeGives A BriefOutlineof theCanine Stem Cell Therapy Market.

Key Performing Regions (APAC, EMEA, Americas) Along With Their Major Countries Are Detailed In This Report.

Company Profiles, Product Analysis,Marketing Strategies, Emerging Market Segments and Comprehensive Analysis of Canine Stem Cell Therapy Market.

Canine Stem Cell Therapy Market ShareYear-Over-Year Growthof Key Players in Promising Regions.

What is the (North America, South America, Europe, Africa, Middle East, Asia, China, Japan)production, production value, consumption, consumption value, import and exportof Canine Stem Cell Therapy market?

To Get Discount of Canine Stem Cell Therapy Market:https://www.researchmoz.us/enquiry.php?type=D&repid=2081893

Contact:

ResearchMozMr. Rohit Bhisey,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email:[emailprotected]

Browse More Reports Visit @https://www.mytradeinsight.blogspot.com/

View post:
Coronavirus threat to global Good Growth Opportunities in Canine Stem Cell Therapy Market - Cole of Duty

For millions of Americans, though, keeping normalcy at bay for such a long time is a luxury they cant afford. People need to hold onto their jobs. Or find new ones. The streets are filling up with Americans who are responding to one national crisisthat of police brutality and systemic racismin the midst of another. And the economy is in cardiac arrest.

Just last week, to address this, the governor of my state announced an accelerated reopening. In the last weeks, there were about 1,500 new coronavirus cases in our region, an increase of 37 percent. In all these headlines, I can see cracks in the walls Ive built around my mom and my partner. How do we bubble people stay safe as the world moves ahead? In some ways people who are immunocompromised have lived their lives in preparation for all of this, Mamjunder told me.

Not long ago, in response to WIRED's Covid-19 coverage, the publication got an email from a woman named Brandy Stephens whod been diagnosed with acute lymphoblastic leukemia in 2014, when she was 26. She and her husband had a 1-year-old daughter. Her treatment put her in the hospital for 165 days, 35 of them on a ventilator. During that time a mere houseplant could have killed me, she wrote. I had multi-organ failure, my bone marrow died, I had pulmonary embolisms, a partially collapsed lung. Then, a stem cell transplant built her a new immune system. In July 2019, at the five-year mark, Stephens was finally able to be reimmunized, against the scary things that babies are immunized for.

Most of the world does not know we exist, she wrote.

I called her to ask about how she did it. I needed to know how to shepherd my mom and partner through a reopened world. I couldn't eat takeout for a year post-transplant. I carry sanitizer, gloves, masks, Lysol with me. She added, My husband is my rock. It has become second nature to have real quirks, to, say, go to family gatherings but not get close to anyone. She knows how to do this. I feel for people who never have had to isolate before, she added, I went through that struggle. (Immunocompromised people have figured out how to protest too.)

We are lucky to live in an area that has kept the overall coronavirus numbers low, yet the steady tick of reminders about potential Covid-19 resurgences haunt me. For everyone in this pandemic, its hard right now to accurately see a future beyond quarantine. Will we return to normal this year? What does normal mean? Something different for all of us, of course.

Last Friday afternoon I was working at Moms house, and I took a break. We were sitting in her living room, on her lovely blue couches. The dog tucked his head under her arm. Mom asked me what I was looking forward to.

The question jolted me. In pre-corona times, I tried to keep things on the calendar to look forward to. But over the past two months I have shut that instinct down.

Now, my mind ricocheted. Restaurants. Could I look forward to eating at our favorite pizza joint? My partners brother: He just added a new floor at the top of the house, a big glorious room with sliding glass doors that open to a porch overlooking the Pacific. He wants to have parties in that big, cheerful space. Will we be there?

Here are the things I hope to put on my calendar someday soon: dinner at our friends house. Driving with Mom for a day at our favorite beach, without worrying about crowds. Those parties at my partners brothers house, in that big, cheerful space. And if need be, flights to a different city if the new treatments we need for my partners cancer arrive, via a trial, somewhere else.

I hope I can put all of those things on the calendar, for the time we have left together.

More From WIRED on Covid-19

Read the original post:
The Country Is Reopening. Im Still on Lockdown - WIRED

Health care stakeholders need to invest in value-based care, innovative care delivery models, advanced digital technologies. XploreMR will help you to know declarative, procedural, contextual, and somatic information about the Canine Stem Cell Therapy Market. It also provides a critical assessment of the performance of emerging and mature markets in a new publication titled Global Market Study on Canine Stem Cell Therapy: Ongoing Clinical Trials and Focus on Advancements to Push Adoption in Veterinary Clinics.

A synopsis of the global canine stem cell therapy market with reference to the global healthcare pharmaceutical industry

Despite the economic and political uncertainty in the recent past, the global healthcare industry has been receiving positive nudges from reformative and technological disruptions in medical devices, pharmaceuticals and biotech, in-vitro diagnostics, and medical imaging. Key markets across the world are facing a massive rise in demand for critical care services that are pushing global healthcare spending levels to unimaginable limits.

Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) and many more Information:https://www.xploremr.com/connectus/sample/2360

A rapidly multiplying geriatric population; increasing prevalence of chronic ailments such as cancer and cardiac disease; growing awareness among patients; and heavy investments in clinical innovation are just some of the factors that are impacting the performance of the global healthcare industry. Proactive measures such as healthcare cost containment, primary care delivery, innovation in medical procedures (3-D printing, blockchain, and robotic surgery to name a few), safe and effective drug delivery, and well-defined healthcare regulatory compliance models are targeted at placing the sector on a high growth trajectory across key regional markets.

Parent Indicators Healthcare

Research Methodology

XploreMR utilizes a triangulation methodology that is primarily based on experimental techniques such as patient-level data, to obtain precise market estimations and insights on Molecule and Drug Classes, API Formulations and preferred modes of administration. Bottom-up approach is always used to obtain insightful data for the specific country/regions. The country specific data is again analysed to derive data at a global level. This methodology ensures high quality and accuracy of information.

Secondary research is used at the initial phase to identify the age specific disease epidemiology, diagnosis rate and treatment pattern, as per disease indications. Each piece of information is eventually analysed during the entire research project which builds a strong base for the primary research information.

Primary research participants include demand-side users such as key opinion leaders, physicians, surgeons, nursing managers, clinical specialists who provide valuable insights on trends and clinical application of the drugs, key treatment patterns, adoption rate, and compliance rate.

Quantitative and qualitative assessment of basic factors driving demand, economic factors/cycles and growth rates and strategies utilized by key players in the market is analysed in detail while forecasting, in order to project Year-on-Year growth rates. These Y-o-Y growth projections are checked and aligned as per industry/product lifecycle and further utilized to develop market numbers at a holistic level.

On the other hand, we also analyse various companies annual reports, investor presentations, SEC filings, 10k reports and press release operating in this market segment to fetch substantial information about the market size, trends, opportunity, drivers, restraints and to analyse key players and their market shares. Key companies are segmented at Tier level based on their revenues, product portfolio and presence.

Please note that these are the partial steps that are being followed while developing the market size. Besides this, forecasting will be done based on our internal proprietary model which also uses different macro-economic factors such as per capita healthcare expenditure, disposable income, industry based demand driving factors impacting the market and its forecast trends apart from disease related factors.

Get Full Access Of This Exclusive Report Right Now: https://www.xploremr.com/cart/2360/SL

Standard Report Structure

Target Audience

Market Taxonomy

The global canine stem cell therapy market has been segmented into:

Product Type:

Application:

End User:

Region:

Read more:
Canine Stem Cell Therapy Market to Expand with Significant CAGR - WorldsTrend

Many people have found much success with Pet Stem Cell Therapy, and this form of regenerative therapy can be applied to your beloved dogs as well. Stem cell treatments maximize the animals natural healing capabilities, provides relief, and promote overall quality of life. It may be quite the expense, but they have some benefits which cannot be replicated by traditional medicine.

Stem cells are blank slates. They are uncharacterized and unspecialized cells that can grow and divide into many types, like muscle, blood, or organ cells. Stem cells serve as a repair mechanism, removing and replacing problematic cells and tissues by turning into the needed cells and reproducing.

Stem cell treatment promotes repair and growth of damaged, dysfunctional, or diseased tissues through the utilization of stem cells. Through this, stem cell therapy is often referred to as regenerative medicine. When done right, stem cell treatment enables the repair and healing of damaged organs.

However, stem cell treatment is not a cure-all. They are more common when dealing with problems in the muscles and bone marrows, where stem cells can routinely and reliably repair damages. But in specific organs, such as the pancreas and heart, stem cells can only reproduce under special conditions and circumstances. Stem cells are not panaceas; specific systems benefit more than others.

The basic idea in stem cell therapy for pets is the same as for humans. But because there are fewer medical regulations with animals than with humans, this regenerative process is used more with pets.

Pet stem cell therapy takes cells from the fat, bone marrow, umbilical cord, or blood of your pet or another animal with the same species, then injects them into the damaged area. The cells then get to work on the damages and cause new, healthy cells to grow, which will turn into unadulterated, healthy tissue.

Stem cell surgery is not for every pet, though. It will not magically cure the illness of your pet, and worse, it may cause adverse side effects. It is not for every budget bracket, either. Sessions can cost upwards of thousands of dollars, however, if it is for your pet care then it is worth it. Inquire a veterinarian about stem cell treatments and ask many inquiries about the procedure for pets.

Inflammation is caused by the immune systems response to foreign organisms. It is the bodys attempt at protecting itself by signaling the immune system to heal damages and defend from invaders. It is the same with dogs; inflammation is caused by the acting up of the immune system and the secretions of the white blood cells.

Stem cell treatments can be used to suppress or cure inflammation. Numerous studies cite the importance of Mesenchymal stem cells (MSCs) to counteract immune response and suppress inflammation for both humans and dogs.

In some instances, however, the immune system of both humans and animals dont work the way they were intended to be. Sometimes, the bodys defense response triggers an inflammation, even when there is nothing to fight off. These autoimmune diseases treat tissues as under attack of foreign invaders, even when there is no infection. Because of this, the bodys tissues are harmed.

In Pet Stem Cell Therapy, Adult Mesenchymal stem cells can be injected into affected joints. MSCs release anti-inflammatory enzymes that help relieve pain.

After ligament, tendon, or cartilage damage, the natural healing response takes over. But normal healing often results in scar formation and inferior tissue that fails to copy the original function, composition, and structure of the damaged part.

Regenerative healing suppresses inflammatory cells, and certain studies show that with Pet Stem Cell Therapy, MSCs improve tissue strength levels when compared to the still intact tissue.

Skeletal and muscle injuries are very common and may result from a wide variety of causes and mechanisms such as strains, lacerations, wounds, or over-exhaustion, which also affect dogs.

The transplanting of stem cells into the damaged or aberrant tissue is a central tenet of tissue engineering and regenerative medicine. Presently, the majority of reports treating skeletal and muscle injuries are limited mainly to animal experiments, and they produced positive results.

Degenerative diseases in dogs, such as degenerative myelopathy (a progressive condition in the spinal cord) and degenerative joint disease can be helped by pet stem cell therapy.

Owners report an improvement in mobility and range during the first few days and weeks of the procedure. Studies also show evidence in slowing the progression and the possible reversion of these rare, neurological diseases.

Pet stem cell therapy is mainly safe for your dogs, as the cells are harvested directly from your pet. However, stem cell treatments are looked down upon as cancer treatment because of its risk of causing cancer to worsen or spread more rapidly. Other than rest and support, minimal care is required for dogs after the procedure. Entrust your pet to a veterinarian with ample training and experience in regenerative medicine.

These are just some of the benefits of pet stem cell therapy. They can be successfully be used in a variety of treatments. However, research is still limited and the exact extent of avantages and even disadvantages is unknown. Like all treatments, Pet stem cell therapy also has side effects and limitations, it is best to do complete research and talk to an experianced vet who can guide you in the right decision. They will be better able to provide you the ifs and dont about how stem cell treatments can help your dog and their condition.

Read Out More Article5 Smart Reasons to Buy Pet Insurance Policy Now10 Cutest Dogs on Instagram12 Fictional Animal Sidekicks We Always Wanted But Cant Have

Follow this link:
Pet Stem Cell Therapy: How It Can Be A Life Saver For Your ...